// App-Quantinova.ai

2014 : NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi).

Researchers

Presenter

  • Kurt A. Jaeckle

Principal Investigators

  • David Schiff

  • Patrick J. Flynn

  • Jann Nagina Sarkaria

  • Caterina Giannini

  • Bradley J. Erickson

  • Jan C Buckner

  • S. Keith Anderson

  • Evanthia Galanis

  • Philip J. Stella

Medical Centers

  • Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN

  • Mayo Clinic, Jacksonville, FLUniversity of Virginia Medical Center, Charlottesville, VASaint Joseph Mercy Health System, Ann Arbor, MI

  • Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • Circulating tumor cells

  • Vascular endothelial growth factor A

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Temozolomide

  • Temsirolimus

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT00329719

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved